Montelukast Ur (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Ur, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children. GNH USA supplies Montelukast Ur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast Ur belongs to the leukotriene receptor antagonist class and is indicated for several allergic airway conditions. - Asthma: improves long‑term control and reduces the frequency of exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing, itching and rhinorrhea. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Montelukast may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea: occasional upset stomach. - Sore throat: mild irritation. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or throat. - Allergic reactions: rash, hives or anaphylaxis. - Mood changes: depression, anxiety or suicidal thoughts. - Stevens‑Johnson syndrome: severe skin reactions. - Eosinophilic pneumonia: respiratory distress with eosinophil infiltration. - Hepatic injury: abnormal liver function tests.

Before prescribing Montelukast, clinicians should consider several safety measures. - Assess asthma control: ensure baseline therapy is optimized. - Monitor neuropsychiatric events: watch for mood changes or suicidal ideation. - Use caution in hepatic impairment: adjust therapy if liver function is compromised. - Avoid in patients with known hypersensitivity to montelukast or any component of the formulation. - Store at room temperature: keep in the original pack, protect from moisture.

Montelukast can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Phenobarbital: enzyme induction may lower montelukast levels. - Rifampin: strong inducer of metabolism, reducing effectiveness. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase systemic exposure. - Concurrent leukotriene modifiers: risk of additive adverse effects.

Moderate Interactions (Monitor Closely): - Antidepressants: monitor for enhanced neuropsychiatric symptoms. - Antihistamines: possible additive effect on allergy control. - Beta‑agonists: observe for changes in bronchodilator response. - Warfarin: monitor INR for potential interaction.